With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

Now that Takeda has lined up its $62 billion deal to buy Shire $SHPG, without working too hard to line up the money, Porges decided to bring out the calculator to see what industry leaders could do if they really wanted to buy Something Big.